Dosing regimen of meropenem for adults with severe burns: A population pharmacokinetic study with Monte Carlo simulations

Journal of Antimicrobial Chemotherapy

Volumn 70, Issue 3, 2015, Pages 882-890

  Ramon Lopez, Amelia ^a,b   Allen, Jane M ^c   Thomson, Alison H ^a,d   Dheansa, Bajlit S ^c   Elizabeth James, S ^e   Hanlon, Geoff W ^e   Stewart, Bruce ^f   Graham Davies, J ^g  

^a UNIVERSITY OF STRATHCLYDE   (United Kingdom)

^b MIGUEL HERNÁNDEZ UNIVERSITY   (Spain)

^c QUEEN VICTORIA HOSPITAL   (United Kingdom)

^d WESTERN INFIRMARY   (United Kingdom)

^e UNIVERSITY OF BRIGHTON   (United Kingdom)

^f SURREY AND SUSSEX HEALTHCARE NHS TRUST   (United Kingdom)

^g KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

Antibiotics; Carbapenems; Intensive care; Pharmacodynamics; PK

Indexed keywords

ALBUMIN; MEROPENEM; ANTIINFECTIVE AGENT; THIENAMYCIN DERIVATIVE;

ADULT; AGED; ARTICLE; BACTERIAL STRAIN; BODY SURFACE; BURN; CLINICAL ARTICLE; CONTINUOUS INFUSION; DISTRIBUTION HALF-LIFE; DRUG DOSE REGIMEN; DRUG EFFICACY; ELIMINATION HALF-LIFE; ENTEROCOCCUS FAECALIS; ESCHERICHIA COLI; FEMALE; HOSPITAL ADMISSION; HUMAN; LIMIT OF DETECTION; LIMIT OF QUANTITATION; MALE; MIDDLE AGED; MINIMUM INHIBITORY CONCENTRATION; MONTE CARLO METHOD; NONHUMAN; PHARMACOKINETICS; PSEUDOMONAS AERUGINOSA; BACTERIAL INFECTIONS; CHEMISTRY; COMPLICATION; INTRAVENOUS DRUG ADMINISTRATION; PLASMA; TIME;

ADMINISTRATION, INTRAVENOUS; ADULT; AGED; ANTI-BACTERIAL AGENTS; BACTERIAL INFECTIONS; BURNS; FEMALE; HUMANS; MALE; MIDDLE AGED; MONTE CARLO METHOD; PLASMA; THIENAMYCINS; TIME FACTORS;

EID: 84928181751     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dku429     Document Type: Article

References (44)

1. Pruitt BA Jr. The diagnosis and treatment of infection in the burn patient. Burns Incl Therm Inj 1984; 11: 79-91.
2. Revathi G, Puri J, Jain BK. Bacteriology of burns. Burns 1998; 24: 347-9.
3. Donati L, Scamazzo F, Gervasoni M et al. Infection and antibiotic therapy in 4000 burned patients treated in Milan, Italy, between 1976 and 1988. Burns 1993; 19: 345-8.
4. Blanchet B, Jullien V, Vinsonneau C et al. Influence of burns on pharmacokinetics and pharmacodynamics of drugs used in the care of burn patients. Clin Pharmacokinet 2008; 47: 635-54.
5. Weinbren MJ. Pharmacokinetics of antibiotics in burn patients. J Antimicrob Chemother 1999; 44: 319-27.
6. Zaske DE, Sawchuk RJ, Gerding DN et al. Increased dosage requirements of gentamicin in burns patients. J Trauma 1976; 16: 824-8.
7. Garrelts JC, Peterie JD. Altered vancomycin dose vs. serum concentration relationship in burn patients. Clin Pharmacol Ther 1988; 44: 9-13.
8. Garrelts JC, Jost G, Kowalsky SF et al. Ciprofloxacin pharmacokinetics in burn patients. Antimicrob Agents Chemother 1996; 40: 1153-6.
9. Bourget P, Lesne-Hulin A, Le Reveille R et al. Clinical pharmacokinetics of piperacillin-tazobactam combination in patients with major burns and signs of infection. Antimicrob Agents Chemother 1996; 40: 139-45.
10. Doh K, Woo H, Hur J et al. Population pharmacokinetics of meropenem in burn patients. J Antimicrob Chemother 2010; 65: 2428-35.
11. Lin C, Liu SQ, Dai Q et al. Pharmacokinetics of meropenem in the patients with burn injury. Chin J Antibiot 2004; 29: 118-23.
12. Hallam MJ, Allen JM, James SE et al. Potential subtherapeutic linezolid and meropenem antibiotic concentrations in a patient with severe burns and sepsis. J Burn Care Res 2010; 31: 207-9.
13. Drusano GL. Prevention of resistance: a goal for dose selection for antimicrobial agents. Clin Infect Dis 2003; 36 Suppl 1: S42-50.
14. Bui KQ, Ambrose PG, Nicolau DP et al. Pharmacokinetics of high-dose meropenemin adult cystic fibrosis patients. Chemotherapy 2001; 47: 153-6.
15. Krueger WA, Bulitta J, Kinzig-Schippers M et al. Evaluation by Monte Carlo simulation of the pharmacokinetics of two doses of meropenem administered intermittently or as a continuous infusion in healthy volunteers. Antimicrob Agents Chemother 2005; 49: 1881-9.
16. Lee DG, Choi SM, Shin WS et al. Population pharmacokinetics of meropenem in febrile neutropenic patients in Korea. Int J Antimicrob Agents 2006; 28: 333-9.
17. Santos Filho L, Eagye KJ, Kuti JL et al. Addressing resistance evolution in Pseudomonas aeruginosa using pharmacodynamic modelling: application to meropenem dosage and combination therapy. Clin Microbiol Infect 2007; 13: 579-85.
18. Roberts JA, Kirkpatrick CMJ, Roberts MS et al. Meropenem dosing in critically ill patients with sepsis and without renal dysfunction: intermittent bolus versus continuous administration? Monte Carlo dosing simulations and subcutaneous tissue distribution. J Antimicrob Chemother 2009; 64: 142-50.
19. Ikawa K, Morikawa N, Ohge H et al. Pharmacokinetic-pharmacodynamic target attainment analysis of meropenem in Japanese adult patients. J Infect Chemother 2010; 16: 25-32.
20. EUCAST. Breakpoint Tables for Interpretation of MICs and Zone Diameters. http://www.eucast.org/antimicrobial_susceptibility_testing/breakpoints/.
21. Turner PJ. MYSTIC Europe 2007: activity of meropenem and other broad-spectrum agents against nosocomial isolates. Diagn Microbiol Infect Dis 2009; 63: 217-22.
22. Kuti JL, Dandekar PK, Nightingale CH et al. Use of Monte Carlo simulation to design an optimized pharmacodynamic dosing strategy for meropenem. J Clin Pharmacol 2003; 43: 1116-23.
23. Tobiasen J, Hiebert JM, Edlich RF. The abbreviated burn severity index. Ann Emerg Med 1982; 11: 260-2.
24. Elkhaili H, Niedergang S, Pompei D et al. High-performance liquid chromatographic assay for meropenem in serum. J Chromatogr B Biomed Appl 1996; 686: 19-26.
25. Lovering AM, Vickery CJ, Watkin DS et al. The pharmacokinetics of meropenem in surgical patients with moderate or severe infections. J Antimicrob Chemother 1995; 36: 165-72.
26. Beal S, Sheiner LB, Boeckmann A et al. NONMEM User's Guides (1989-2009). Ellicott City, MD: Icon Development Solutions, 2009.
27. Venables WN, Smith DM, R Development Core Team. R Version 2.1.4.0. The R Foundation for Statistical Computing. http://www.r-project.org/foundation/main.html.
28. Jonsson EN, Karlsson MO. Xpose-an S-PLUS based population pharmacokinetic/pharmacodynamic model building aid for NONMEM. Comput Methods Programs Biomed 1999; 58: 51-64.
29. Karlsson MO, Savic RM. Diagnosing model diagnostics. Clin Pharmacol Ther 2007; 82: 17-20.
30. Wahlby U, Jonsson EN, Karlsson MO. Comparison of stepwise covariate model building strategies in population pharmacokinetic-pharmacodynamic analysis. AAPS PharmSci 2002; 4: E27.
31. Lindbom L, Pihlgren P, Jonsson EN. PsN-Toolkit-a collection of computer intensive statistical methods for non-linear mixed effect modeling using NONMEM. Comput Methods Programs Biomed 2005; 79: 241-57.
32. Bergstrand M, Hooker AC, Wallin JE et al. Prediction-corrected visual predictive checks for diagnosing nonlinear mixed-effects models. AAPS J 2011; 13: 143-51.
33. Brendel K, Comets E, Laffont C et al. Metrics for external model evaluation with an application to the population pharmacokinetics of gliclazide. Pharm Res 2006; 23: 2036-49.
34. Mouton JW, Dudley MN, Cars O et al. Standardization of pharmacokinetic/pharmacodynamic (PK/PD) terminology for anti-infective drugs: an update. J Antimicrob Chemother 2005; 55: 601-7.
35. Li C, Kuti JL, Nightingale CH et al. Population pharmacokinetic analysis and dosing regimen optimization of meropenem in adult patients. J Clin Pharmacol 2006; 46: 1171-8.
36. Christensson BA, Nilsson-Ehle I, Hutchison M et al. Pharmacokinetics of meropenem in subjects with various degrees of renal impairment. Antimicrob Agents Chemother 1992; 36: 1532-7.
37. Cockcroft DW, Gault H. Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16: 1-41.
38. Conil JM, Georges B, Fourcade O et al. Assessment of renal function in clinical practice at the bedside of burn patients. Br J Clin Pharmacol 2007; 63: 583-94.
39. Ariano RE, Nyhlen A, Donnelly JP et al. Pharmacokinetics and pharmacodynamics of meropenem in febrile neutropenic patients with bacteremia. Ann Pharmacother 2005; 39: 32-8.
40. McKinnon PS, Paladino JA, Schentag JJ. Evaluation of area under the inhibitory curve (AUIC) and time above the minimum inhibitory concentration (T>MIC) as predictors of outcome for cefepime and ceftazidime in serious bacterial infections. Int J Antimicrob Agents 2008; 31: 345-51.
41. Bulik CC, Quintiliani R, Samuel J et al. Pharmacodynamics and tolerability of high-dose, prolonged infusion carbapenems in adults with cystic fibrosis-a review of 3 cases. Respir Med CME 2010; 3: 146-9.
42. Bulik CC, Christensen H, Peng Li P et al. Comparison of the activity of a human simulated, high-dose, prolonged infusion of meropenem against Klebsiella pneumoniae producing the KPC carbapenemase versus that against Pseudomonas aeruginosa in an in vitro pharmacodynamic model. Antimicrob Agents Chemother 2010; 54: 804-10.
43. Roberts JA, Kirkpatrick CA, Roberts MS et al. Meropenem dosing in critically ill patientswith sepsis and without renal dysfunction: intermittent bolus versus continuous administration?Monte Carlo dosing simulations and subcutaneous tissue distribution. J Antimicrob Chemother 2009; 64: 142-50.
44. Berthoin K, Le Duff CS, Marchand-Brynaert J et al. Stability of meropenem and doripenem solutions for administration by continuous infusion. J Antimicrob Chemother 2010; 65: 1073-5.